Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment

12/01/2021 | 02:41pm EST


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
01/17Johnson & Johnson Statement on New Mexico Opioid Settlement Agreement
AQ
01/17MARKETSCREENER’S WORLD PRESS REVIEW : January 17, 2022
01/17Midatech Pharma, Janssen Extend R&D Partnership On Experimental Medicine
MT
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
01/13Divco West Real Estate Services, LLC acquired 143,000 square feet, 5000 Shoreline Court..
CI
01/12Johnson & Johnson's COVID-19 Vaccine Fact Sheet Updated to Include Risk of Rare Bleedin..
MT
01/12South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Booster..
MT
01/11US FDA Adds Risk of Rare Bleeding Disorder to Johnson & Johnson COVID-19 Jab's Fact She..
MT
01/11Mix and Match Covid-19 Vaccine Study to Take Place in Mozambique
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 306 M - -
Net income 2021 22 542 M - -
Net Debt 2021 596 M - -
P/E ratio 2021 19,8x
Yield 2021 2,49%
Capitalization 439 B 439 B -
EV / Sales 2021 4,66x
EV / Sales 2022 4,34x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 166,58 $
Average target price 183,50 $
Spread / Average Target 10,2%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
ABBVIE INC.-0.14%239 035
NOVO NORDISK A/S-12.67%223 059
ELI LILLY AND COMPANY-11.28%222 160